Overview
Biomolecular condensates are increasingly recognized as key regulators of cancer biology, influencing processes such as transcription, chromatin organization, DNA-damage responses, RNA splicing, oncogenic signaling, and therapeutic resistance. This joint hybrid workshop from NCI’s Division of Cancer Treatment and Diagnosis (DCTD) and Division of Cancer Biology (DCB) will bring together leaders from academia, industry, and NIH to explore how advances in condensate biology can be translated into clinically meaningful biomarkers, diagnostics, and therapies.
Over two days, the workshop will address the foundations of condensate biology in cancer, emerging platforms to measure condensate states and function, approaches for linking condensate measurements to cancer-relevant phenotypes, and therapeutic strategies targeting condensate-driven mechanisms. Industry case studies and NIH partnership and funding pathways will further highlight opportunities to accelerate translation from discovery to clinical application.
Workshop Co-chairs:
- Richard A. Young, Ph.D., Massachusetts Institute of Technology
- Cigall Kadoch, Ph.D., Dana-Farber Cancer Institute
Workshop Committee:
- Jung Byun, Ph.D., M.P.H., Diagnostic Biomarkers and Technology Branch, CDP/DCTD
- Brian Sorg, Ph.D., M.B.A., Diagnostic Biomarkers and Technology Branch (Chief), CDP/DCTD
- Zhang-Zhi Hu, M.D., ImmunoOncology Branch, DTP/DCTD
- Ian Fingerman, Ph.D., DNA and Chromosome Aberrations Research Branch (Chief), DCB
- Hannah Dueck, Ph.D., Biophysics, Bioengineering, and Computational Sciences Branch, DCB
- Eric Johnson Chavarria, Ph.D., Biophysics, Bioengineering & Computational Sciences Branch, DCB
- Stefan Maas, Ph.D., Cancer Cell Biology Branch, DCB